Does TRICARE Cover Belsomra (Suvorexant)?

TRICARE Formulary Placement for Belsomra

Belsomra is listed on the TRICARE Uniform Formulary as a non-preferred, Tier 3 medication. That classification means TRICARE will pay for it, but at a higher cost-share than preferred sleep aids like generic zolpidem or trazodone. The Department of Defense Pharmacy and Therapeutics Committee reviews formulary placement annually, and Belsomra has remained in this non-preferred position since its inclusion.

For beneficiaries filling prescriptions at a military treatment facility (MTF) pharmacy, the copay is $0 regardless of tier. Retail network pharmacies carry higher copays for Tier 3 drugs, typically $53 for a 30-day supply under TRICARE Prime and TRICARE Select. Mail-order through Express Scripts (the TRICARE pharmacy contractor) offers a 90-day supply at a reduced per-unit cost. Suvorexant was the first dual orexin receptor antagonist (DORA) approved by the FDA in 2014 1, and its novel mechanism of action is one reason it remains classified separately from older, less expensive hypnotics on the TRICARE formulary.

The TRICARE formulary search tool at militaryrx.express-scripts.com provides real-time tier status. Beneficiaries should check this tool before each refill, since formulary tier assignments can shift during the annual review cycle.

Prior Authorization Requirements

TRICARE requires prior authorization (PA) for Belsomra across all plan types, including Prime, Select, and TRICARE For Life. The PA process is handled by Express Scripts on behalf of the Defense Health Agency.

To obtain approval, the prescribing provider must submit clinical documentation showing the beneficiary meets specific criteria. The standard requirements include a confirmed diagnosis of insomnia disorder per DSM-5 criteria, documented trial and failure (or contraindication) of at least one preferred formulary sleep medication, and a clinical rationale explaining why Belsomra is medically necessary for the individual patient. "Failure" typically means the patient experienced inadequate response after an adequate trial duration (usually 2 to 4 weeks) or developed intolerable side effects 2.

The PA difficulty level is moderate. Most requests that include proper documentation of step therapy compliance are approved within 72 hours for standard requests and 24 hours for urgent requests. Providers can submit PA requests electronically through the Express Scripts provider portal or by fax. Incomplete submissions are the most common cause of initial denial. A 2019 analysis of TRICARE pharmacy claims found that prior authorization approval rates for non-preferred sleep medications exceeded 70% when the prescriber included specific documentation of prior drug trials and outcomes 3.

Step Therapy Before Belsomra

TRICARE applies step therapy protocols for Belsomra. This means beneficiaries must try and fail a preferred-tier medication before TRICARE will approve coverage. The step therapy sequence is not arbitrary. It reflects the DoD P&T Committee's assessment of clinical equivalence and cost.

The first-line preferred agents for insomnia on the TRICARE formulary include generic zolpidem (immediate-release and extended-release), eszopiclone (generic Lunesta), and low-dose doxepin. Trazodone, while prescribed off-label for insomnia, also counts as a step therapy attempt in many cases. Beneficiaries who have a documented allergy to Z-drugs (zolpidem, eszopiclone, zaleplon) or a medical reason for avoiding them (such as a history of complex sleep behaviors) can often bypass step therapy with appropriate clinical documentation.

The HealthRX clinical team uses a four-checkpoint framework when helping patients prepare step therapy documentation for TRICARE DORA coverage:

1. Drug name and dates. Record the exact generic name, dose, and start/stop dates for each previously tried medication.
2. Outcome measurement. Document the specific reason for discontinuation: lack of efficacy (using a validated tool like the Insomnia Severity Index if possible), side effects (name them), or contraindication.
3. Provider attestation. A signed statement from the prescriber confirming that Belsomra is the preferred clinical choice given the patient's medication history, comorbidities, and treatment goals.
4. Comorbidity flags. Note any conditions that make orexin receptor antagonism preferable, such as substance use history (where GABA-ergic hypnotics carry higher misuse risk), respiratory compromise, or advanced age.

This documentation structure aligns with the criteria Express Scripts evaluates and can reduce PA processing time to under 48 hours.

How to Appeal a TRICARE Denial of Belsomra

When TRICARE denies Belsomra coverage, beneficiaries have the right to appeal. The denial letter will include the specific reason for the decision, a reference to the formulary policy, and instructions for filing an appeal.

The first level of appeal is a reconsideration request submitted to Express Scripts within 60 days of the denial. The prescriber should include any additional clinical information that addresses the stated reason for denial. If the initial PA was denied for insufficient step therapy documentation, the appeal should include updated records showing prior drug trials, including dates, dosages, and outcomes. If the denial was based on a missing diagnosis code, resubmission with the correct ICD-10 code (G47.00 for insomnia, unspecified, or G47.01 for adjustment insomnia) often resolves the issue.

If the first-level appeal is unsuccessful, beneficiaries can escalate to a formal TRICARE appeal through the regional contractor. TRICARE Prime enrollees file with their regional managed care support contractor. TRICARE For Life beneficiaries file through the TFL claims processor. The formal appeal must be filed in writing, and the beneficiary can include supporting letters from their provider, sleep study results, and records of prior treatment failures.

A peer-to-peer review, where the prescribing physician speaks directly with an Express Scripts clinical pharmacist, can sometimes resolve denials more quickly than the written appeal process. Providers can request this by calling the Express Scripts PA line. According to TRICARE's own published guidance, peer-to-peer reviews result in overturned denials in a meaningful percentage of cases, particularly when the initial denial stemmed from documentation gaps rather than genuine clinical ineligibility 4.

Clinical Evidence Supporting Suvorexant

Suvorexant earned FDA approval based on two Phase III randomized controlled trials. The study by Herring et al., published in The Lancet Neurology in 2012, enrolled 2,035 patients with primary insomnia and compared suvorexant (low dose and high dose) against placebo over 3 months 1. Suvorexant significantly improved both subjective sleep onset latency and total sleep time. Patients on the 20 mg dose fell asleep approximately 10 minutes faster and slept roughly 23 minutes longer than those on placebo.

The drug's safety profile is well characterized. The most common adverse effects are next-day somnolence (reported in 7% of patients vs. 3% on placebo) and headache. Unlike benzodiazepines and Z-drugs, suvorexant does not produce significant respiratory depression, making it a consideration for patients with mild obstructive sleep apnea. A 2020 pooled safety analysis (N=3,291) published in CNS Drugs found no evidence of rebound insomnia after discontinuation and low rates of withdrawal symptoms 5.

Dr. Andrew Krystal, a sleep medicine researcher at UCSF and lead investigator on several DORA trials, has stated: "Orexin receptor antagonists represent a fundamentally different pharmacological strategy for insomnia. Rather than broadly sedating the brain, they target the specific wake-promoting pathway, which is why we see a cleaner side-effect profile in most patients."

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia recommends suvorexant as one of several options for adults, with the strength of recommendation rated "weak" due to limited comparative effectiveness data against first-line agents at the time of publication 6.

Cost-Saving Strategies for TRICARE Beneficiaries

Even with TRICARE coverage, Belsomra can be expensive at retail pharmacies. The manufacturer list price is approximately $340 per month. Several strategies can lower out-of-pocket costs.

The MTF pharmacy option remains the most cost-effective route. Prescriptions filled at military pharmacies carry a $0 copay, including Tier 3 drugs. If the MTF pharmacy stocks Belsomra, this eliminates cost entirely. Not all MTF pharmacies carry every formulary drug, so beneficiaries should call ahead. The TRICARE mail-order pharmacy program through Express Scripts offers 90-day supplies at reduced copays. For Tier 3 drugs, the mail-order copay is typically $53 for a 90-day supply (compared to $53 per 30 days at retail), making this the second-best option after MTF.

Federal law prohibits TRICARE beneficiaries from using manufacturer copay assistance cards or savings programs. This restriction applies to all government-funded insurance, including TRICARE, VA, and Medicare Part D. The Merck Belsomra savings card is available only to commercially insured patients, and using it with TRICARE can result in claims fraud allegations.

For beneficiaries who lose coverage or face high out-of-pocket costs, the Merck Patient Assistance Program may provide Belsomra at no cost to qualifying low-income individuals. The eligibility criteria and application forms are available at merckhelps.com. Generic suvorexant is not yet available as of mid-2026, but beneficiaries should ask their provider about lemborexant (Dayvigo), another DORA-class medication that may have different formulary placement on TRICARE.

Suvorexant vs. Other TRICARE-Covered Sleep Medications

Choosing between Belsomra and preferred-tier alternatives depends on the patient's clinical profile. Generic zolpidem (Tier 1, $0 at MTF, ~$14 at retail) remains the most commonly prescribed sleep medication on TRICARE. It works faster than suvorexant for sleep onset but carries a higher risk of complex sleep behaviors, tolerance, and dependency. The FDA issued a 2013 safety communication lowering recommended zolpidem doses, particularly for women, after reports of next-morning impairment 7.

Eszopiclone (generic Lunesta, Tier 2) has a longer half-life than zolpidem and produces durable efficacy over 6-month studies without evidence of tolerance. Its main drawback is a metallic or unpleasant taste reported by up to 34% of users.

Low-dose doxepin (Silenor, 3 or 6 mg) is FDA-approved for insomnia characterized by difficulty with sleep maintenance. It does not carry a DEA schedule classification, which gives it an advantage for patients with substance use disorder histories. Suvorexant is Schedule IV, which means it carries some abuse potential, though the actual rates of misuse in clinical practice are very low.

The newer DORA, lemborexant (Dayvigo), was approved in 2019 and may have different TRICARE formulary placement. In a head-to-head Phase III trial (SUNRISE-1, N=1,006), lemborexant 10 mg demonstrated superior sleep-onset latency reduction compared to zolpidem ER 6.25 mg at the end of the first month, though both drugs performed similarly by month 6 8.

Special Populations and TRICARE Plan Variations

TRICARE coverage rules for Belsomra apply uniformly across most beneficiary categories, with a few exceptions worth noting.

Active duty service members enrolled in TRICARE Prime can fill Belsomra at their MTF pharmacy with no copay. If the MTF does not stock the drug, the prescriber can request a non-formulary override or refer the patient to retail or mail-order. Active duty members have $0 copays at all pharmacy points of service, so the financial distinction between tiers is less relevant for this population.

Retirees and dependents under TRICARE Select face the standard Tier 3 copay at retail pharmacies. TRICARE For Life beneficiaries (those with both TRICARE and Medicare Part B) should check whether Medicare Part D covers suvorexant at a lower tier, since Part D plans vary. In most cases, TRICARE For Life acts as a secondary payer and covers remaining costs after Medicare processes the claim.

TRICARE Overseas beneficiaries may face additional barriers. Belsomra may not be available at overseas MTF pharmacies, and international retail pharmacies may not participate in the Express Scripts network. These beneficiaries should coordinate with their TRICARE Overseas Program contractor for guidance on obtaining non-formulary medications abroad.

Pregnant or breastfeeding patients should note that suvorexant is rated FDA Pregnancy Category C, based on animal data showing adverse developmental effects at high doses. The AASM and the American College of Obstetricians and Gynecologists recommend nonpharmacologic approaches such as CBT-I as first-line treatment for insomnia during pregnancy 9.